Edward Tenthoff
Stock Analyst at Piper Sandler
(3.26)
# 1,092
Out of 5,124 analysts
191
Total ratings
44.75%
Success rate
3.06%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $70 → $100 | $66.39 | +50.63% | 13 | Dec 17, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $20 → $45 | $28.86 | +55.93% | 2 | Dec 10, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $98 → $125 | $77.81 | +60.65% | 5 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $16 → $23 | $11.31 | +103.36% | 6 | Dec 8, 2025 | |
| MRNA Moderna | Reiterates: Overweight | $69 → $63 | $29.49 | +113.63% | 13 | Nov 21, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Overweight | $5 → $6 | $1.74 | +244.83% | 2 | Nov 14, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $397.65 | +22.97% | 15 | Oct 31, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $7.36 | +63.04% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $6.13 | +95.76% | 2 | Sep 15, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $14.19 | +5.71% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $52.44 | +100.23% | 7 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $11.57 | +72.86% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.24 | +464.52% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 → $14 | $11.86 | +18.04% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $0.99 | +101.05% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $19.56 | +145.40% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $18.04 | +33.04% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $21.74 | +258.79% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $15.31 | +95.95% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $2.87 | +2,164.81% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.75 | +2,567.73% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.26 | +138.10% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.31 | +882.32% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $15.68 | +2.04% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $0.98 | +510.62% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.02 | +147.52% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $33.87 | +632.21% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $4.00 | +2,150.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $14.85 | +1,112.12% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.10 | +157.31% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.05 | +424.82% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $9.43 | +124,301,066.49% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $840.95 | -57.90% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.12 | +11,953.57% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $453.36 | -28.75% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.21 | +144.86% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $43.83 | -17.86% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.49 | +1,577.85% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.59 | +25,497.27% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.49 | +2,789,469.44% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $771.87 | - | 11 | Feb 13, 2017 |
Arrowhead Pharmaceuticals
Dec 17, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $66.39
Upside: +50.63%
Capricor Therapeutics
Dec 10, 2025
Reiterates: Overweight
Price Target: $20 → $45
Current: $28.86
Upside: +55.93%
Kymera Therapeutics
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $77.81
Upside: +60.65%
Fulcrum Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $11.31
Upside: +103.36%
Moderna
Nov 21, 2025
Reiterates: Overweight
Price Target: $69 → $63
Current: $29.49
Upside: +113.63%
Inovio Pharmaceuticals
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.74
Upside: +244.83%
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $397.65
Upside: +22.97%
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $7.36
Upside: +63.04%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $6.13
Upside: +95.76%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $14.19
Upside: +5.71%
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $52.44
Upside: +100.23%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $11.57
Upside: +72.86%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.24
Upside: +464.52%
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $11.86
Upside: +18.04%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.99
Upside: +101.05%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $19.56
Upside: +145.40%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $18.04
Upside: +33.04%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $21.74
Upside: +258.79%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $15.31
Upside: +95.95%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $2.87
Upside: +2,164.81%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.75
Upside: +2,567.73%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.26
Upside: +138.10%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.31
Upside: +882.32%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $15.68
Upside: +2.04%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $0.98
Upside: +510.62%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $2.02
Upside: +147.52%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $33.87
Upside: +632.21%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $4.00
Upside: +2,150.00%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $14.85
Upside: +1,112.12%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.10
Upside: +157.31%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.05
Upside: +424.82%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $9.43
Upside: +124,301,066.49%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $840.95
Upside: -57.90%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.12
Upside: +11,953.57%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $453.36
Upside: -28.75%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.21
Upside: +144.86%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $43.83
Upside: -17.86%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.49
Upside: +1,577.85%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.59
Upside: +25,497.27%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.49
Upside: +2,789,469.44%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $771.87
Upside: -